| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Medication Adherence | 99 | 2024 | 2187 | 14.260 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 43 | 2023 | 3251 | 4.180 |
Why?
|
| Cardiovascular Agents | 20 | 2019 | 849 | 4.180 |
Why?
|
| Insurance, Pharmaceutical Services | 15 | 2019 | 348 | 3.300 |
Why?
|
| Drug Prescriptions | 28 | 2024 | 1667 | 2.950 |
Why?
|
| Antihypertensive Agents | 21 | 2023 | 2029 | 2.810 |
Why?
|
| Drugs, Generic | 21 | 2016 | 455 | 2.740 |
Why?
|
| Hypertension | 25 | 2023 | 8616 | 2.720 |
Why?
|
| Hypoglycemic Agents | 20 | 2021 | 3108 | 2.640 |
Why?
|
| Prescription Drugs | 17 | 2023 | 635 | 2.550 |
Why?
|
| Chronic Disease | 20 | 2021 | 9384 | 2.430 |
Why?
|
| Community Pharmacy Services | 6 | 2019 | 52 | 2.310 |
Why?
|
| Drug Costs | 24 | 2023 | 1195 | 2.270 |
Why?
|
| Pharmaceutical Services | 7 | 2018 | 143 | 2.100 |
Why?
|
| Cost Sharing | 14 | 2020 | 409 | 1.970 |
Why?
|
| Myocardial Infarction | 34 | 2022 | 11519 | 1.970 |
Why?
|
| Health Expenditures | 16 | 2023 | 2389 | 1.900 |
Why?
|
| Patient Compliance | 15 | 2019 | 2697 | 1.890 |
Why?
|
| Insurance Claim Review | 15 | 2020 | 743 | 1.700 |
Why?
|
| Drug Utilization | 15 | 2018 | 1190 | 1.620 |
Why?
|
| Inappropriate Prescribing | 3 | 2024 | 212 | 1.500 |
Why?
|
| Reminder Systems | 5 | 2018 | 388 | 1.490 |
Why?
|
| Warfarin | 11 | 2018 | 1493 | 1.450 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 13 | 2020 | 1515 | 1.420 |
Why?
|
| Coronary Artery Bypass | 9 | 2015 | 2191 | 1.420 |
Why?
|
| United States | 109 | 2024 | 73027 | 1.340 |
Why?
|
| Adrenergic beta-Antagonists | 12 | 2020 | 1243 | 1.330 |
Why?
|
| Diabetes Mellitus, Type 2 | 15 | 2025 | 12252 | 1.310 |
Why?
|
| Pharmacists | 5 | 2019 | 261 | 1.290 |
Why?
|
| Insurance Coverage | 12 | 2016 | 1946 | 1.280 |
Why?
|
| Drug Labeling | 7 | 2016 | 250 | 1.280 |
Why?
|
| Prescriptions | 4 | 2023 | 388 | 1.260 |
Why?
|
| Diabetes Mellitus | 17 | 2021 | 5887 | 1.240 |
Why?
|
| Pharmacies | 12 | 2021 | 171 | 1.210 |
Why?
|
| Cardiovascular Diseases | 27 | 2023 | 15660 | 1.190 |
Why?
|
| Ticlopidine | 9 | 2016 | 730 | 1.170 |
Why?
|
| Atrial Fibrillation | 16 | 2018 | 5182 | 1.140 |
Why?
|
| Humans | 294 | 2025 | 767991 | 1.130 |
Why?
|
| Anticoagulants | 15 | 2019 | 4854 | 1.120 |
Why?
|
| Platelet Aggregation Inhibitors | 15 | 2020 | 2764 | 1.110 |
Why?
|
| Polypharmacy | 4 | 2021 | 307 | 1.110 |
Why?
|
| Hyperlipidemias | 7 | 2018 | 772 | 1.080 |
Why?
|
| Insurance, Health | 9 | 2017 | 2517 | 1.040 |
Why?
|
| Cost Savings | 7 | 2019 | 904 | 0.980 |
Why?
|
| Female | 166 | 2025 | 397113 | 0.980 |
Why?
|
| Health Benefit Plans, Employee | 3 | 2015 | 332 | 0.970 |
Why?
|
| Male | 155 | 2025 | 364641 | 0.960 |
Why?
|
| Cohort Studies | 55 | 2025 | 41749 | 0.960 |
Why?
|
| Middle Aged | 116 | 2025 | 223422 | 0.950 |
Why?
|
| Metformin | 6 | 2023 | 909 | 0.940 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 7 | 2022 | 285 | 0.930 |
Why?
|
| Medicare | 21 | 2020 | 6809 | 0.910 |
Why?
|
| Medication Therapy Management | 5 | 2018 | 131 | 0.910 |
Why?
|
| Aged | 106 | 2024 | 171446 | 0.900 |
Why?
|
| Thiophenes | 5 | 2014 | 570 | 0.890 |
Why?
|
| Physicians | 12 | 2022 | 4598 | 0.860 |
Why?
|
| Blood Pressure | 8 | 2023 | 8540 | 0.860 |
Why?
|
| Secondary Prevention | 9 | 2020 | 1474 | 0.850 |
Why?
|
| Commerce | 5 | 2016 | 612 | 0.850 |
Why?
|
| Cost-Benefit Analysis | 24 | 2020 | 5536 | 0.850 |
Why?
|
| Patient-Centered Care | 5 | 2017 | 1444 | 0.840 |
Why?
|
| Drug Substitution | 3 | 2016 | 291 | 0.830 |
Why?
|
| Postprandial Period | 1 | 2025 | 320 | 0.830 |
Why?
|
| Physical Therapy Modalities | 2 | 2023 | 533 | 0.810 |
Why?
|
| Prescription Fees | 7 | 2014 | 153 | 0.790 |
Why?
|
| Cost Control | 6 | 2017 | 627 | 0.790 |
Why?
|
| Insulin | 5 | 2020 | 6606 | 0.760 |
Why?
|
| Telemedicine | 4 | 2021 | 3109 | 0.750 |
Why?
|
| Alopecia Areata | 1 | 2023 | 130 | 0.730 |
Why?
|
| Telephone | 5 | 2022 | 630 | 0.720 |
Why?
|
| Health Care Costs | 6 | 2020 | 3239 | 0.710 |
Why?
|
| Blood Glucose | 5 | 2025 | 6429 | 0.710 |
Why?
|
| Electronic Health Records | 6 | 2021 | 4884 | 0.650 |
Why?
|
| Uncompensated Care | 2 | 2009 | 37 | 0.640 |
Why?
|
| Angiotensin Receptor Antagonists | 5 | 2020 | 1065 | 0.640 |
Why?
|
| Quality of Health Care | 10 | 2018 | 4310 | 0.640 |
Why?
|
| Reinforcement, Social | 1 | 2018 | 10 | 0.640 |
Why?
|
| beta-Alanine | 3 | 2014 | 82 | 0.630 |
Why?
|
| Quality-Adjusted Life Years | 9 | 2019 | 1741 | 0.630 |
Why?
|
| Hypolipidemic Agents | 5 | 2018 | 609 | 0.630 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2018 | 30 | 0.630 |
Why?
|
| Logistic Models | 17 | 2021 | 13289 | 0.620 |
Why?
|
| Medical Assistance | 2 | 2009 | 108 | 0.620 |
Why?
|
| Patient Education as Topic | 7 | 2016 | 2336 | 0.610 |
Why?
|
| Retrospective Studies | 47 | 2024 | 81746 | 0.610 |
Why?
|
| Postal Service | 1 | 2018 | 96 | 0.610 |
Why?
|
| Osteoporosis | 4 | 2017 | 1605 | 0.600 |
Why?
|
| Metoprolol | 1 | 2018 | 90 | 0.600 |
Why?
|
| Patient Participation | 2 | 2017 | 1446 | 0.600 |
Why?
|
| Healthcare Disparities | 6 | 2016 | 3414 | 0.590 |
Why?
|
| Myocardial Revascularization | 6 | 2016 | 795 | 0.580 |
Why?
|
| Spinal Diseases | 1 | 2022 | 561 | 0.580 |
Why?
|
| Financing, Organized | 2 | 2009 | 203 | 0.580 |
Why?
|
| Frail Elderly | 1 | 2023 | 781 | 0.570 |
Why?
|
| Financing, Personal | 5 | 2014 | 310 | 0.570 |
Why?
|
| Glycemic Index | 1 | 2020 | 400 | 0.560 |
Why?
|
| Self Report | 7 | 2023 | 3773 | 0.560 |
Why?
|
| Vaccination | 3 | 2023 | 3437 | 0.560 |
Why?
|
| Health Insurance Portability and Accountability Act | 1 | 2017 | 105 | 0.560 |
Why?
|
| Analgesics, Opioid | 7 | 2023 | 3837 | 0.560 |
Why?
|
| Medicare Part D | 3 | 2015 | 355 | 0.560 |
Why?
|
| Pyridones | 4 | 2017 | 819 | 0.550 |
Why?
|
| Insurance Carriers | 2 | 2021 | 159 | 0.540 |
Why?
|
| Conflict of Interest | 3 | 2011 | 556 | 0.540 |
Why?
|
| Benzimidazoles | 4 | 2015 | 863 | 0.530 |
Why?
|
| Randomized Controlled Trials as Topic | 13 | 2021 | 10396 | 0.530 |
Why?
|
| Patient Preference | 3 | 2019 | 946 | 0.530 |
Why?
|
| Adult | 64 | 2025 | 223583 | 0.530 |
Why?
|
| Pharmaceutical Preparations | 4 | 2016 | 1086 | 0.520 |
Why?
|
| Fee-for-Service Plans | 2 | 2020 | 713 | 0.520 |
Why?
|
| Coronary Disease | 7 | 2011 | 5919 | 0.520 |
Why?
|
| Morpholines | 3 | 2014 | 584 | 0.520 |
Why?
|
| Medicare Part C | 1 | 2021 | 332 | 0.520 |
Why?
|
| Diabetes Complications | 2 | 2020 | 1319 | 0.510 |
Why?
|
| Hospitalization | 10 | 2024 | 10840 | 0.510 |
Why?
|
| Complementary Therapies | 1 | 2020 | 487 | 0.510 |
Why?
|
| Medical Staff, Hospital | 3 | 2024 | 602 | 0.500 |
Why?
|
| Comparative Effectiveness Research | 4 | 2017 | 714 | 0.500 |
Why?
|
| Pharmacy Service, Hospital | 1 | 2016 | 134 | 0.500 |
Why?
|
| New Jersey | 5 | 2020 | 296 | 0.490 |
Why?
|
| Medical Informatics | 1 | 2022 | 743 | 0.490 |
Why?
|
| Drug Industry | 6 | 2012 | 791 | 0.490 |
Why?
|
| Immunization | 1 | 2019 | 1218 | 0.480 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2013 | 246 | 0.480 |
Why?
|
| Drug Therapy, Combination | 14 | 2017 | 6314 | 0.480 |
Why?
|
| Decision Support Systems, Clinical | 2 | 2018 | 1178 | 0.470 |
Why?
|
| Medication Reconciliation | 1 | 2016 | 153 | 0.470 |
Why?
|
| Administration, Oral | 9 | 2019 | 4030 | 0.470 |
Why?
|
| Databases, Factual | 18 | 2018 | 8082 | 0.470 |
Why?
|
| Low Back Pain | 1 | 2023 | 990 | 0.470 |
Why?
|
| Renal Dialysis | 3 | 2012 | 1791 | 0.460 |
Why?
|
| Guideline Adherence | 6 | 2014 | 2235 | 0.460 |
Why?
|
| Research Design | 8 | 2021 | 6211 | 0.460 |
Why?
|
| Guidelines as Topic | 2 | 2020 | 1395 | 0.450 |
Why?
|
| Deductibles and Coinsurance | 4 | 2020 | 315 | 0.450 |
Why?
|
| Aged, 80 and over | 32 | 2024 | 59598 | 0.440 |
Why?
|
| Propensity Score | 11 | 2018 | 1970 | 0.440 |
Why?
|
| Wounds and Injuries | 2 | 2024 | 2515 | 0.440 |
Why?
|
| Health Services Needs and Demand | 3 | 2022 | 1406 | 0.440 |
Why?
|
| Treatment Outcome | 37 | 2024 | 65364 | 0.440 |
Why?
|
| Primary Health Care | 7 | 2023 | 4746 | 0.440 |
Why?
|
| Imidazoles | 2 | 2017 | 1168 | 0.440 |
Why?
|
| Diphosphonates | 2 | 2017 | 634 | 0.440 |
Why?
|
| Pharmacogenetics | 2 | 2014 | 682 | 0.430 |
Why?
|
| Cost of Illness | 3 | 2015 | 1951 | 0.430 |
Why?
|
| Confidentiality | 1 | 2017 | 607 | 0.430 |
Why?
|
| Models, Economic | 4 | 2019 | 719 | 0.420 |
Why?
|
| Pharyngitis | 1 | 2014 | 221 | 0.410 |
Why?
|
| Socioeconomic Factors | 12 | 2020 | 7851 | 0.410 |
Why?
|
| United States Food and Drug Administration | 11 | 2015 | 1671 | 0.410 |
Why?
|
| Stockings, Compression | 1 | 2012 | 36 | 0.410 |
Why?
|
| Drug Recalls | 1 | 2012 | 20 | 0.410 |
Why?
|
| Age Factors | 13 | 2024 | 18407 | 0.400 |
Why?
|
| Quality Improvement | 3 | 2020 | 3855 | 0.400 |
Why?
|
| Evidence-Based Medicine | 9 | 2019 | 3701 | 0.400 |
Why?
|
| Otitis Media | 1 | 2014 | 288 | 0.390 |
Why?
|
| Medical Records | 1 | 2017 | 1409 | 0.390 |
Why?
|
| Time Factors | 21 | 2024 | 40214 | 0.390 |
Why?
|
| Cephalosporins | 1 | 2013 | 200 | 0.390 |
Why?
|
| Pain, Postoperative | 4 | 2017 | 1765 | 0.390 |
Why?
|
| Intention to Treat Analysis | 3 | 2018 | 416 | 0.390 |
Why?
|
| Patients | 3 | 2010 | 908 | 0.390 |
Why?
|
| Quality Assurance, Health Care | 3 | 2010 | 2175 | 0.390 |
Why?
|
| Renal Insufficiency | 2 | 2016 | 812 | 0.380 |
Why?
|
| Pyrazoles | 4 | 2017 | 2028 | 0.380 |
Why?
|
| Decision Making | 6 | 2022 | 3952 | 0.380 |
Why?
|
| Postoperative Complications | 6 | 2018 | 15831 | 0.380 |
Why?
|
| Coronary Artery Disease | 5 | 2013 | 6569 | 0.380 |
Why?
|
| Blood Loss, Surgical | 1 | 2015 | 642 | 0.380 |
Why?
|
| Practice Guidelines as Topic | 9 | 2019 | 7445 | 0.370 |
Why?
|
| Kidney Failure, Chronic | 3 | 2012 | 2496 | 0.370 |
Why?
|
| Markov Chains | 5 | 2015 | 979 | 0.370 |
Why?
|
| Ambulatory Care Facilities | 2 | 2014 | 939 | 0.370 |
Why?
|
| Drug Approval | 2 | 2011 | 820 | 0.370 |
Why?
|
| Life Change Events | 1 | 2016 | 960 | 0.370 |
Why?
|
| Costs and Cost Analysis | 3 | 2014 | 1666 | 0.370 |
Why?
|
| Enterocolitis, Pseudomembranous | 1 | 2013 | 264 | 0.360 |
Why?
|
| Referral and Consultation | 5 | 2022 | 3619 | 0.360 |
Why?
|
| Health Behavior | 2 | 2022 | 2650 | 0.360 |
Why?
|
| Disclosure | 3 | 2011 | 755 | 0.350 |
Why?
|
| Cesarean Section | 2 | 2017 | 1425 | 0.350 |
Why?
|
| Health Services Accessibility | 7 | 2015 | 5520 | 0.350 |
Why?
|
| Data Collection | 4 | 2015 | 3326 | 0.350 |
Why?
|
| Communication | 6 | 2022 | 3904 | 0.350 |
Why?
|
| Pharmacy | 2 | 2022 | 92 | 0.350 |
Why?
|
| Renal Insufficiency, Chronic | 2 | 2018 | 2298 | 0.350 |
Why?
|
| Medication Errors | 3 | 2016 | 784 | 0.350 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2012 | 345 | 0.350 |
Why?
|
| Matched-Pair Analysis | 3 | 2013 | 285 | 0.340 |
Why?
|
| Capital Financing | 1 | 2010 | 58 | 0.340 |
Why?
|
| Legislation, Drug | 2 | 2014 | 216 | 0.340 |
Why?
|
| Piperazines | 4 | 2017 | 2552 | 0.340 |
Why?
|
| Anticonvulsants | 3 | 2016 | 1922 | 0.340 |
Why?
|
| Medicaid | 7 | 2019 | 2840 | 0.340 |
Why?
|
| Vancomycin | 1 | 2013 | 504 | 0.340 |
Why?
|
| Specialization | 1 | 2014 | 779 | 0.330 |
Why?
|
| Technology | 2 | 2023 | 296 | 0.330 |
Why?
|
| Influenza, Human | 2 | 2018 | 1541 | 0.330 |
Why?
|
| Patient Discharge | 6 | 2018 | 3476 | 0.330 |
Why?
|
| Risk Factors | 27 | 2023 | 74936 | 0.330 |
Why?
|
| Vascular Diseases | 2 | 2008 | 1162 | 0.330 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2018 | 3231 | 0.330 |
Why?
|
| Pharmacy Administration | 1 | 2009 | 3 | 0.330 |
Why?
|
| Voluntary Health Agencies | 1 | 2009 | 38 | 0.330 |
Why?
|
| Pennsylvania | 8 | 2019 | 615 | 0.330 |
Why?
|
| Encephalitozoon | 1 | 2009 | 4 | 0.320 |
Why?
|
| Internationality | 3 | 2014 | 1008 | 0.320 |
Why?
|
| Nonprescription Drugs | 2 | 2012 | 119 | 0.320 |
Why?
|
| Fluorobenzenes | 1 | 2011 | 179 | 0.320 |
Why?
|
| Aromatase Inhibitors | 1 | 2013 | 519 | 0.320 |
Why?
|
| Industry | 2 | 2010 | 362 | 0.320 |
Why?
|
| Heart Failure | 6 | 2024 | 11883 | 0.320 |
Why?
|
| Publications | 1 | 2011 | 195 | 0.320 |
Why?
|
| Family | 3 | 2018 | 3210 | 0.310 |
Why?
|
| Bone Density Conservation Agents | 4 | 2015 | 797 | 0.310 |
Why?
|
| Economic Competition | 2 | 2008 | 223 | 0.310 |
Why?
|
| Quality Indicators, Health Care | 3 | 2020 | 1805 | 0.310 |
Why?
|
| Urinary Tract Infections | 1 | 2014 | 804 | 0.300 |
Why?
|
| Risk Assessment | 18 | 2024 | 24314 | 0.300 |
Why?
|
| Food Supply | 1 | 2014 | 544 | 0.300 |
Why?
|
| Aspirin | 4 | 2013 | 3135 | 0.290 |
Why?
|
| Antidepressive Agents | 2 | 2017 | 2913 | 0.290 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2013 | 640 | 0.290 |
Why?
|
| Health Records, Personal | 1 | 2009 | 127 | 0.290 |
Why?
|
| Drug and Narcotic Control | 2 | 2008 | 145 | 0.290 |
Why?
|
| Enterocytes | 1 | 2009 | 220 | 0.280 |
Why?
|
| Renin-Angiotensin System | 1 | 2012 | 737 | 0.280 |
Why?
|
| Odds Ratio | 10 | 2024 | 9666 | 0.280 |
Why?
|
| Young Adult | 21 | 2019 | 60048 | 0.280 |
Why?
|
| Blood Pressure Determination | 2 | 2022 | 646 | 0.280 |
Why?
|
| Patient Care | 2 | 2020 | 629 | 0.280 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2010 | 388 | 0.280 |
Why?
|
| Health Status Disparities | 2 | 2016 | 1885 | 0.280 |
Why?
|
| Hepatitis C, Chronic | 1 | 2015 | 1032 | 0.270 |
Why?
|
| Income | 5 | 2020 | 1878 | 0.270 |
Why?
|
| Genetic Testing | 3 | 2014 | 3589 | 0.260 |
Why?
|
| Models, Statistical | 3 | 2017 | 5107 | 0.260 |
Why?
|
| Product Surveillance, Postmarketing | 3 | 2015 | 463 | 0.260 |
Why?
|
| Prevalence | 6 | 2021 | 15867 | 0.260 |
Why?
|
| Stroke | 11 | 2019 | 9755 | 0.260 |
Why?
|
| Antithrombins | 3 | 2018 | 294 | 0.260 |
Why?
|
| Long-Term Care | 3 | 2020 | 631 | 0.260 |
Why?
|
| Follow-Up Studies | 13 | 2020 | 39345 | 0.260 |
Why?
|
| Managed Care Programs | 1 | 2011 | 939 | 0.260 |
Why?
|
| American Heart Association | 2 | 2021 | 1050 | 0.260 |
Why?
|
| Anti-Arrhythmia Agents | 2 | 2018 | 775 | 0.260 |
Why?
|
| Cardiac Tamponade | 1 | 2007 | 175 | 0.260 |
Why?
|
| Intracranial Hemorrhages | 1 | 2011 | 810 | 0.250 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 4205 | 0.250 |
Why?
|
| Drug Utilization Review | 5 | 2016 | 248 | 0.250 |
Why?
|
| Multivariate Analysis | 7 | 2016 | 12075 | 0.250 |
Why?
|
| Evidence-Based Practice | 3 | 2019 | 500 | 0.250 |
Why?
|
| Pain | 3 | 2024 | 5100 | 0.250 |
Why?
|
| Heart Diseases | 2 | 2015 | 2819 | 0.250 |
Why?
|
| Polysaccharides | 1 | 2012 | 1024 | 0.250 |
Why?
|
| Financing, Government | 1 | 2009 | 473 | 0.250 |
Why?
|
| Antiviral Agents | 2 | 2015 | 3073 | 0.250 |
Why?
|
| Internship and Residency | 2 | 2024 | 5952 | 0.250 |
Why?
|
| Biomedical Research | 2 | 2020 | 3463 | 0.250 |
Why?
|
| Health Personnel | 3 | 2021 | 3385 | 0.240 |
Why?
|
| Sulfonamides | 2 | 2015 | 1982 | 0.240 |
Why?
|
| Simvastatin | 4 | 2015 | 346 | 0.240 |
Why?
|
| Benzodiazepines | 3 | 2024 | 1138 | 0.240 |
Why?
|
| Health Resources | 1 | 2011 | 950 | 0.240 |
Why?
|
| Pericardial Effusion | 1 | 2007 | 246 | 0.240 |
Why?
|
| Social Support | 4 | 2022 | 2193 | 0.240 |
Why?
|
| Angina, Unstable | 2 | 2009 | 893 | 0.240 |
Why?
|
| Brain Ischemia | 3 | 2018 | 3007 | 0.240 |
Why?
|
| Financial Support | 3 | 2020 | 116 | 0.240 |
Why?
|
| Thiazolidinediones | 3 | 2014 | 460 | 0.240 |
Why?
|
| Therapeutic Equivalency | 3 | 2015 | 134 | 0.240 |
Why?
|
| Hemorrhage | 8 | 2020 | 3467 | 0.230 |
Why?
|
| Phlebotomy | 1 | 2005 | 138 | 0.230 |
Why?
|
| Depressive Disorder | 1 | 2017 | 3721 | 0.230 |
Why?
|
| Efficiency, Organizational | 1 | 2009 | 697 | 0.230 |
Why?
|
| Patient Readmission | 1 | 2018 | 3288 | 0.230 |
Why?
|
| Health Care Reform | 4 | 2016 | 1256 | 0.230 |
Why?
|
| Drug Administration Schedule | 6 | 2018 | 4857 | 0.230 |
Why?
|
| Epilepsy | 2 | 2016 | 3327 | 0.220 |
Why?
|
| Reimbursement, Incentive | 1 | 2009 | 541 | 0.220 |
Why?
|
| Cross Infection | 1 | 2013 | 1426 | 0.220 |
Why?
|
| India | 2 | 2025 | 2334 | 0.220 |
Why?
|
| Surgical Wound Infection | 1 | 2013 | 1546 | 0.220 |
Why?
|
| Multiple Sclerosis | 1 | 2019 | 3250 | 0.220 |
Why?
|
| Psychotropic Drugs | 1 | 2009 | 881 | 0.220 |
Why?
|
| Seizures | 1 | 2016 | 2998 | 0.220 |
Why?
|
| Vascular Surgical Procedures | 3 | 2024 | 1506 | 0.210 |
Why?
|
| Acute Coronary Syndrome | 2 | 2013 | 2194 | 0.210 |
Why?
|
| National Health Programs | 2 | 1997 | 442 | 0.210 |
Why?
|
| Patient Protection and Affordable Care Act | 3 | 2016 | 1188 | 0.210 |
Why?
|
| Adolescent | 17 | 2019 | 89155 | 0.210 |
Why?
|
| Sulfonylurea Compounds | 3 | 2014 | 220 | 0.210 |
Why?
|
| Hip Fractures | 2 | 2008 | 997 | 0.210 |
Why?
|
| Limb Salvage | 2 | 2023 | 488 | 0.210 |
Why?
|
| Meta-Analysis as Topic | 2 | 2006 | 1363 | 0.210 |
Why?
|
| Physician-Patient Relations | 4 | 2016 | 3269 | 0.210 |
Why?
|
| Nursing Homes | 1 | 2010 | 1084 | 0.200 |
Why?
|
| Internet | 5 | 2016 | 3110 | 0.200 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2009 | 2258 | 0.200 |
Why?
|
| Resuscitation Orders | 2 | 2003 | 271 | 0.200 |
Why?
|
| Delivery of Health Care | 3 | 2022 | 5366 | 0.200 |
Why?
|
| Developing Countries | 2 | 2014 | 2913 | 0.200 |
Why?
|
| Radius Fractures | 1 | 2008 | 515 | 0.200 |
Why?
|
| Absorptiometry, Photon | 1 | 2008 | 1758 | 0.190 |
Why?
|
| Sex Factors | 6 | 2024 | 10627 | 0.190 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2015 | 2271 | 0.190 |
Why?
|
| Cross-Cultural Comparison | 1 | 2005 | 638 | 0.190 |
Why?
|
| Hospital Mortality | 1 | 2015 | 5349 | 0.190 |
Why?
|
| Gout | 2 | 2021 | 621 | 0.190 |
Why?
|
| Cholesterol, LDL | 1 | 2011 | 2403 | 0.190 |
Why?
|
| Heart Rate | 2 | 2010 | 4215 | 0.190 |
Why?
|
| Prospective Studies | 11 | 2025 | 54924 | 0.180 |
Why?
|
| Surgical Procedures, Operative | 4 | 2018 | 1932 | 0.180 |
Why?
|
| Proportional Hazards Models | 5 | 2015 | 12536 | 0.180 |
Why?
|
| Continuity of Patient Care | 1 | 2008 | 1078 | 0.180 |
Why?
|
| Program Evaluation | 5 | 2021 | 2506 | 0.180 |
Why?
|
| Choice Behavior | 2 | 2019 | 848 | 0.180 |
Why?
|
| Qualitative Research | 2 | 2022 | 3140 | 0.180 |
Why?
|
| Incidence | 9 | 2018 | 21532 | 0.180 |
Why?
|
| Health Policy | 6 | 2020 | 2698 | 0.180 |
Why?
|
| Fees, Pharmaceutical | 2 | 2014 | 66 | 0.170 |
Why?
|
| Interferon-gamma | 1 | 2009 | 3159 | 0.170 |
Why?
|
| Clinical Competence | 3 | 2006 | 4857 | 0.170 |
Why?
|
| Forecasting | 3 | 2018 | 2945 | 0.170 |
Why?
|
| Acute Kidney Injury | 1 | 2012 | 1942 | 0.170 |
Why?
|
| Quality of Life | 5 | 2024 | 13489 | 0.170 |
Why?
|
| Needs Assessment | 2 | 2017 | 1141 | 0.170 |
Why?
|
| Hypercholesterolemia | 1 | 2006 | 1145 | 0.170 |
Why?
|
| Patient Satisfaction | 3 | 2021 | 3488 | 0.160 |
Why?
|
| Medical Oncology | 1 | 2011 | 2341 | 0.160 |
Why?
|
| Risk | 4 | 2018 | 9609 | 0.160 |
Why?
|
| Heart Murmurs | 1 | 1999 | 92 | 0.160 |
Why?
|
| Attitude of Health Personnel | 3 | 2015 | 3929 | 0.160 |
Why?
|
| Alopecia | 1 | 2023 | 416 | 0.160 |
Why?
|
| Sensitivity and Specificity | 5 | 2020 | 14718 | 0.160 |
Why?
|
| Beneficence | 2 | 2009 | 56 | 0.160 |
Why?
|
| Behavior Control | 1 | 2019 | 46 | 0.160 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 2 | 2014 | 317 | 0.160 |
Why?
|
| Clinical Trials as Topic | 4 | 2011 | 8052 | 0.160 |
Why?
|
| Toluidines | 1 | 2019 | 21 | 0.160 |
Why?
|
| Primary Prevention | 1 | 2006 | 1188 | 0.160 |
Why?
|
| Crotonates | 1 | 2019 | 21 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2012 | 1883 | 0.160 |
Why?
|
| Herpes Zoster Vaccine | 1 | 2019 | 49 | 0.160 |
Why?
|
| Case-Control Studies | 5 | 2016 | 22287 | 0.160 |
Why?
|
| C-Reactive Protein | 1 | 2011 | 3858 | 0.160 |
Why?
|
| Caregivers | 1 | 2011 | 2302 | 0.160 |
Why?
|
| Behavioral Sciences | 1 | 2018 | 29 | 0.160 |
Why?
|
| Hydroxybutyrates | 1 | 2019 | 76 | 0.160 |
Why?
|
| Posture | 1 | 2023 | 957 | 0.160 |
Why?
|
| Pyrimidines | 1 | 2011 | 3046 | 0.150 |
Why?
|
| Peripheral Arterial Disease | 2 | 2023 | 1304 | 0.150 |
Why?
|
| Combined Modality Therapy | 3 | 2022 | 8535 | 0.150 |
Why?
|
| Trauma Centers | 1 | 2024 | 951 | 0.150 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2004 | 788 | 0.150 |
Why?
|
| Education, Medical | 1 | 2010 | 1742 | 0.150 |
Why?
|
| Patient Selection | 3 | 2019 | 4258 | 0.150 |
Why?
|
| Endovascular Procedures | 3 | 2023 | 2216 | 0.150 |
Why?
|
| Education, Distance | 1 | 2021 | 260 | 0.150 |
Why?
|
| Smoking | 4 | 2016 | 9089 | 0.150 |
Why?
|
| Comorbidity | 5 | 2020 | 10590 | 0.150 |
Why?
|
| Models, Econometric | 2 | 2009 | 215 | 0.140 |
Why?
|
| Remote Consultation | 1 | 2020 | 242 | 0.140 |
Why?
|
| Canada | 5 | 2021 | 2129 | 0.140 |
Why?
|
| Anemia | 2 | 2005 | 1514 | 0.140 |
Why?
|
| Informed Consent | 3 | 2013 | 1010 | 0.140 |
Why?
|
| Adenosine Diphosphate | 1 | 2018 | 422 | 0.140 |
Why?
|
| Teaching Rounds | 1 | 2021 | 282 | 0.140 |
Why?
|
| Coronary Angiography | 1 | 2009 | 4541 | 0.140 |
Why?
|
| Disease Progression | 5 | 2020 | 13665 | 0.140 |
Why?
|
| Recurrence | 5 | 2019 | 8507 | 0.140 |
Why?
|
| Decision Making, Organizational | 1 | 1997 | 136 | 0.140 |
Why?
|
| Minnesota | 2 | 2009 | 339 | 0.140 |
Why?
|
| Proton Pump Inhibitors | 2 | 2013 | 551 | 0.130 |
Why?
|
| Women's Health | 1 | 2006 | 2082 | 0.130 |
Why?
|
| Physical Examination | 4 | 2009 | 1263 | 0.130 |
Why?
|
| Physician Incentive Plans | 1 | 2017 | 165 | 0.130 |
Why?
|
| Sulfasalazine | 1 | 2016 | 85 | 0.130 |
Why?
|
| Ethics Committees, Research | 1 | 2017 | 196 | 0.130 |
Why?
|
| Decision Support Techniques | 2 | 2017 | 2008 | 0.130 |
Why?
|
| Organizational Innovation | 2 | 2016 | 540 | 0.130 |
Why?
|
| Hypnotics and Sedatives | 1 | 2024 | 1191 | 0.130 |
Why?
|
| Community Health Planning | 1 | 2016 | 164 | 0.130 |
Why?
|
| Immunization Programs | 1 | 2018 | 267 | 0.130 |
Why?
|
| Names | 1 | 2015 | 54 | 0.130 |
Why?
|
| Interprofessional Relations | 1 | 2002 | 997 | 0.130 |
Why?
|
| Spine | 1 | 2022 | 1140 | 0.130 |
Why?
|
| Pneumococcal Vaccines | 1 | 2019 | 414 | 0.130 |
Why?
|
| Pyridines | 2 | 2017 | 2893 | 0.130 |
Why?
|
| Morbidity | 2 | 2013 | 1754 | 0.120 |
Why?
|
| Minority Groups | 1 | 2023 | 1217 | 0.120 |
Why?
|
| Privacy | 1 | 2017 | 233 | 0.120 |
Why?
|
| Organizational Policy | 2 | 1994 | 435 | 0.120 |
Why?
|
| Public Opinion | 1 | 2019 | 485 | 0.120 |
Why?
|
| Models, Theoretical | 3 | 2016 | 3573 | 0.120 |
Why?
|
| Vaccines | 1 | 2023 | 842 | 0.120 |
Why?
|
| Anti-Bacterial Agents | 2 | 2013 | 7470 | 0.120 |
Why?
|
| Cross-Sectional Studies | 10 | 2024 | 26375 | 0.120 |
Why?
|
| Xanthine Oxidase | 1 | 2015 | 69 | 0.120 |
Why?
|
| Minority Health | 1 | 2015 | 79 | 0.120 |
Why?
|
| Lisinopril | 1 | 2015 | 60 | 0.120 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2003 | 997 | 0.120 |
Why?
|
| Aortic Valve Insufficiency | 1 | 1999 | 577 | 0.120 |
Why?
|
| Counseling | 1 | 2022 | 1554 | 0.120 |
Why?
|
| Delayed-Action Preparations | 1 | 2018 | 968 | 0.120 |
Why?
|
| Uridine Monophosphate | 1 | 2015 | 67 | 0.120 |
Why?
|
| Attitude to Health | 4 | 2014 | 2024 | 0.120 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2023 | 1883 | 0.120 |
Why?
|
| Residence Characteristics | 2 | 2015 | 2118 | 0.120 |
Why?
|
| Insulin, Long-Acting | 1 | 2014 | 59 | 0.120 |
Why?
|
| Ketorolac | 1 | 2015 | 95 | 0.120 |
Why?
|
| Disease Management | 3 | 2015 | 2533 | 0.120 |
Why?
|
| Ischemia | 3 | 2023 | 1900 | 0.120 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 13658 | 0.110 |
Why?
|
| Health Care Rationing | 1 | 1997 | 435 | 0.110 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2014 | 428 | 0.110 |
Why?
|
| Authorship | 2 | 2011 | 289 | 0.110 |
Why?
|
| Electronic Mail | 1 | 2016 | 215 | 0.110 |
Why?
|
| Genotype | 3 | 2015 | 13042 | 0.110 |
Why?
|
| Reproducibility of Results | 5 | 2015 | 20218 | 0.110 |
Why?
|
| Poverty Areas | 1 | 2015 | 268 | 0.110 |
Why?
|
| Government Regulation | 3 | 2009 | 525 | 0.110 |
Why?
|
| Oseltamivir | 1 | 2014 | 76 | 0.110 |
Why?
|
| Patient Care Team | 2 | 2023 | 2521 | 0.110 |
Why?
|
| Fluorenes | 1 | 2015 | 160 | 0.110 |
Why?
|
| Biotransformation | 1 | 2013 | 166 | 0.110 |
Why?
|
| Pulse | 2 | 2007 | 218 | 0.110 |
Why?
|
| Mesalamine | 1 | 2014 | 134 | 0.110 |
Why?
|
| Carbamates | 1 | 2015 | 192 | 0.110 |
Why?
|
| Nitriles | 1 | 2019 | 980 | 0.110 |
Why?
|
| Information Systems | 1 | 2015 | 400 | 0.110 |
Why?
|
| Angioplasty, Balloon, Coronary | 2 | 2011 | 1724 | 0.110 |
Why?
|
| Professional-Patient Relations | 2 | 2016 | 724 | 0.110 |
Why?
|
| Reimbursement Mechanisms | 2 | 2010 | 670 | 0.110 |
Why?
|
| Valine | 1 | 2015 | 410 | 0.110 |
Why?
|
| Dosage Forms | 1 | 2013 | 56 | 0.110 |
Why?
|
| Gout Suppressants | 1 | 2015 | 176 | 0.110 |
Why?
|
| Information Dissemination | 2 | 2012 | 1142 | 0.110 |
Why?
|
| Ribavirin | 1 | 2015 | 395 | 0.110 |
Why?
|
| Blue Cross Blue Shield Insurance Plans | 1 | 2013 | 92 | 0.110 |
Why?
|
| Pyrrolidines | 1 | 2015 | 340 | 0.110 |
Why?
|
| Life Support Care | 1 | 1994 | 226 | 0.110 |
Why?
|
| Cryptosporidium parvum | 1 | 2013 | 35 | 0.100 |
Why?
|
| Family Practice | 1 | 1996 | 509 | 0.100 |
Why?
|
| Color | 2 | 2013 | 297 | 0.100 |
Why?
|
| Anti-Ulcer Agents | 1 | 2013 | 112 | 0.100 |
Why?
|
| Osteoarthritis, Hip | 1 | 2017 | 409 | 0.100 |
Why?
|
| Advance Directives | 1 | 1994 | 249 | 0.100 |
Why?
|
| Intestinal Diseases, Parasitic | 1 | 2013 | 64 | 0.100 |
Why?
|
| Cryptosporidiosis | 1 | 2013 | 52 | 0.100 |
Why?
|
| Outpatients | 2 | 2017 | 1600 | 0.100 |
Why?
|
| Salaries and Fringe Benefits | 1 | 2015 | 263 | 0.100 |
Why?
|
| Public Policy | 2 | 2008 | 552 | 0.100 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2015 | 296 | 0.100 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2024 | 4055 | 0.100 |
Why?
|
| Artificial Intelligence | 2 | 2024 | 2665 | 0.100 |
Why?
|
| Health Services Misuse | 1 | 2014 | 246 | 0.100 |
Why?
|
| Hydroxychloroquine | 1 | 2016 | 426 | 0.100 |
Why?
|
| Histamine H2 Antagonists | 1 | 2013 | 169 | 0.100 |
Why?
|
| Self Care | 1 | 2017 | 799 | 0.100 |
Why?
|
| alpha-Glucosidases | 1 | 2012 | 46 | 0.100 |
Why?
|
| Case Management | 1 | 2014 | 277 | 0.100 |
Why?
|
| Back Pain | 1 | 2016 | 547 | 0.100 |
Why?
|
| Thiazoles | 2 | 2017 | 1542 | 0.100 |
Why?
|
| Influenza Vaccines | 1 | 2019 | 780 | 0.100 |
Why?
|
| Health Services | 2 | 2013 | 755 | 0.100 |
Why?
|
| Zoonoses | 1 | 2013 | 180 | 0.100 |
Why?
|
| Heptanoic Acids | 3 | 2010 | 344 | 0.100 |
Why?
|
| Patient Care Planning | 1 | 2017 | 905 | 0.100 |
Why?
|
| Vitamin K | 1 | 2014 | 314 | 0.100 |
Why?
|
| Access to Information | 1 | 2014 | 317 | 0.090 |
Why?
|
| Tachycardia, Paroxysmal | 1 | 2011 | 30 | 0.090 |
Why?
|
| Adenosine | 1 | 2016 | 820 | 0.090 |
Why?
|
| Atrioventricular Node | 1 | 2011 | 180 | 0.090 |
Why?
|
| Chi-Square Distribution | 2 | 2007 | 3435 | 0.090 |
Why?
|
| Electrocardiography | 3 | 2010 | 6411 | 0.090 |
Why?
|
| Azetidines | 1 | 2012 | 152 | 0.090 |
Why?
|
| Extremities | 1 | 2016 | 870 | 0.090 |
Why?
|
| Developed Countries | 1 | 2014 | 454 | 0.090 |
Why?
|
| Adaptation, Psychological | 1 | 2021 | 2663 | 0.090 |
Why?
|
| Interferon-alpha | 1 | 2015 | 910 | 0.090 |
Why?
|
| Age Distribution | 1 | 2016 | 2871 | 0.090 |
Why?
|
| Health Services Research | 2 | 2014 | 1815 | 0.090 |
Why?
|
| Clinical Pharmacy Information Systems | 1 | 2010 | 102 | 0.090 |
Why?
|
| Communications Media | 1 | 2010 | 42 | 0.090 |
Why?
|
| Poverty | 2 | 2015 | 2720 | 0.090 |
Why?
|
| Self Medication | 1 | 2011 | 115 | 0.090 |
Why?
|
| Withholding Treatment | 1 | 1994 | 620 | 0.090 |
Why?
|
| Skilled Nursing Facilities | 1 | 1994 | 405 | 0.090 |
Why?
|
| Preoperative Period | 1 | 2012 | 565 | 0.090 |
Why?
|
| North America | 1 | 2014 | 1289 | 0.090 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2014 | 452 | 0.090 |
Why?
|
| Anti-Obesity Agents | 1 | 2013 | 240 | 0.090 |
Why?
|
| Computer Simulation | 3 | 2019 | 6283 | 0.090 |
Why?
|
| Retreatment | 1 | 2011 | 598 | 0.080 |
Why?
|
| Cross-Over Studies | 1 | 2016 | 2107 | 0.080 |
Why?
|
| Drug Interactions | 4 | 2017 | 1419 | 0.080 |
Why?
|
| Organizational Case Studies | 1 | 2010 | 301 | 0.080 |
Why?
|
| Journal Impact Factor | 1 | 2011 | 157 | 0.080 |
Why?
|
| Clinical Audit | 1 | 2009 | 29 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2017 | 21206 | 0.080 |
Why?
|
| Respiratory Tract Diseases | 1 | 2015 | 744 | 0.080 |
Why?
|
| Program Development | 1 | 2016 | 1299 | 0.080 |
Why?
|
| Dermatology | 1 | 2019 | 905 | 0.080 |
Why?
|
| Social Class | 1 | 2018 | 2007 | 0.080 |
Why?
|
| Methotrexate | 1 | 2016 | 1721 | 0.080 |
Why?
|
| Drug Therapy | 1 | 2012 | 504 | 0.080 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2016 | 1126 | 0.080 |
Why?
|
| Sequence Deletion | 1 | 2013 | 1494 | 0.080 |
Why?
|
| Mental Disorders | 1 | 2009 | 6875 | 0.080 |
Why?
|
| Receptors, Estrogen | 1 | 2017 | 2253 | 0.080 |
Why?
|
| Insurance Benefits | 1 | 2010 | 185 | 0.080 |
Why?
|
| Embolism | 1 | 2012 | 401 | 0.080 |
Why?
|
| Hydrochlorothiazide | 1 | 2009 | 95 | 0.080 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2009 | 153 | 0.080 |
Why?
|
| Emergency Medical Services | 1 | 2020 | 1947 | 0.080 |
Why?
|
| Drug Combinations | 1 | 2015 | 2089 | 0.080 |
Why?
|
| Bayes Theorem | 2 | 2015 | 2358 | 0.080 |
Why?
|
| Mixed Function Oxygenases | 1 | 2009 | 265 | 0.070 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2009 | 117 | 0.070 |
Why?
|
| Electrophysiologic Techniques, Cardiac | 1 | 2011 | 511 | 0.070 |
Why?
|
| Pandemics | 2 | 2021 | 8748 | 0.070 |
Why?
|
| Quality Control | 1 | 2011 | 836 | 0.070 |
Why?
|
| Drug Packaging | 1 | 2007 | 44 | 0.070 |
Why?
|
| Anticholesteremic Agents | 2 | 2012 | 972 | 0.070 |
Why?
|
| Hepacivirus | 1 | 2015 | 1342 | 0.070 |
Why?
|
| Glomerular Filtration Rate | 1 | 2016 | 2227 | 0.070 |
Why?
|
| Health Care Surveys | 2 | 2019 | 2433 | 0.070 |
Why?
|
| Pyrroles | 3 | 2010 | 1123 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 15944 | 0.070 |
Why?
|
| Altruism | 1 | 2009 | 211 | 0.070 |
Why?
|
| State Government | 1 | 2010 | 388 | 0.070 |
Why?
|
| Pericardiocentesis | 1 | 2007 | 78 | 0.070 |
Why?
|
| Medical Audit | 1 | 2008 | 454 | 0.070 |
Why?
|
| Lovastatin | 1 | 2007 | 115 | 0.070 |
Why?
|
| Tryptophan | 1 | 2009 | 482 | 0.070 |
Why?
|
| Osteoarthritis, Knee | 1 | 2017 | 1251 | 0.070 |
Why?
|
| Child, Preschool | 5 | 2016 | 42665 | 0.070 |
Why?
|
| Editorial Policies | 1 | 2011 | 458 | 0.070 |
Why?
|
| Arthroplasty, Replacement, Hip | 1 | 2017 | 1417 | 0.070 |
Why?
|
| Antirheumatic Agents | 1 | 2016 | 1381 | 0.070 |
Why?
|
| Arthroplasty, Replacement, Knee | 1 | 2017 | 1389 | 0.070 |
Why?
|
| Factor Analysis, Statistical | 1 | 2009 | 1001 | 0.070 |
Why?
|
| Family Health | 1 | 2011 | 1255 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2008 | 1625 | 0.060 |
Why?
|
| Medical History Taking | 1 | 2009 | 779 | 0.060 |
Why?
|
| Ontario | 2 | 1997 | 403 | 0.060 |
Why?
|
| Biological Products | 1 | 2015 | 948 | 0.060 |
Why?
|
| Heart Conduction System | 1 | 2011 | 1009 | 0.060 |
Why?
|
| Eligibility Determination | 1 | 2009 | 421 | 0.060 |
Why?
|
| Quinolines | 1 | 2011 | 770 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 3 | 2019 | 2708 | 0.060 |
Why?
|
| Cerebral Hemorrhage | 1 | 2016 | 2655 | 0.060 |
Why?
|
| Pulmonary Veins | 1 | 2011 | 761 | 0.060 |
Why?
|
| Hospitals, Special | 1 | 2005 | 89 | 0.060 |
Why?
|
| Pravastatin | 1 | 2007 | 393 | 0.060 |
Why?
|
| Calcitonin | 1 | 2006 | 328 | 0.060 |
Why?
|
| Emergency Service, Hospital | 3 | 2015 | 7939 | 0.060 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 3237 | 0.060 |
Why?
|
| Physician Self-Referral | 1 | 2004 | 16 | 0.060 |
Why?
|
| Economics, Medical | 1 | 2005 | 112 | 0.060 |
Why?
|
| Longitudinal Studies | 3 | 2017 | 14783 | 0.060 |
Why?
|
| Safety | 1 | 2009 | 1159 | 0.060 |
Why?
|
| Privatization | 1 | 2004 | 41 | 0.060 |
Why?
|
| Early Diagnosis | 1 | 2009 | 1193 | 0.060 |
Why?
|
| Postmenopause | 1 | 2013 | 2518 | 0.060 |
Why?
|
| Blood Volume | 1 | 2005 | 545 | 0.060 |
Why?
|
| Hematocrit | 1 | 2005 | 623 | 0.060 |
Why?
|
| Professional Misconduct | 1 | 2004 | 72 | 0.050 |
Why?
|
| Life Style | 1 | 2015 | 3932 | 0.050 |
Why?
|
| Comprehension | 1 | 2009 | 639 | 0.050 |
Why?
|
| Physician's Role | 1 | 2010 | 925 | 0.050 |
Why?
|
| Migraine Disorders | 1 | 2016 | 1713 | 0.050 |
Why?
|
| Liability, Legal | 1 | 2005 | 209 | 0.050 |
Why?
|
| Surgery, Computer-Assisted | 1 | 2011 | 1002 | 0.050 |
Why?
|
| Registries | 1 | 2019 | 8377 | 0.050 |
Why?
|
| Cholinergic Antagonists | 1 | 2024 | 166 | 0.050 |
Why?
|
| Drug Discovery | 1 | 2011 | 1068 | 0.050 |
Why?
|
| Exercise | 1 | 2019 | 5955 | 0.050 |
Why?
|
| Hospitals, Community | 1 | 2005 | 364 | 0.050 |
Why?
|
| Cluster Analysis | 2 | 2020 | 2731 | 0.050 |
Why?
|
| Alleles | 1 | 2013 | 6894 | 0.050 |
Why?
|
| Perception | 1 | 2009 | 1209 | 0.050 |
Why?
|
| Lactones | 2 | 2015 | 316 | 0.050 |
Why?
|
| Selection Bias | 1 | 2004 | 360 | 0.050 |
Why?
|
| Length of Stay | 3 | 2017 | 6495 | 0.050 |
Why?
|
| Health Care Sector | 1 | 2004 | 196 | 0.050 |
Why?
|
| Colitis, Ulcerative | 1 | 2014 | 1926 | 0.050 |
Why?
|
| Weight Loss | 1 | 2013 | 2721 | 0.050 |
Why?
|
| Health Status | 1 | 2015 | 4092 | 0.050 |
Why?
|
| Prognosis | 2 | 2020 | 29979 | 0.050 |
Why?
|
| Pneumonia | 1 | 2013 | 2163 | 0.050 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2008 | 1196 | 0.050 |
Why?
|
| Models, Biological | 1 | 2018 | 9493 | 0.050 |
Why?
|
| Medicine | 1 | 2010 | 945 | 0.050 |
Why?
|
| Educational Status | 1 | 2009 | 2515 | 0.050 |
Why?
|
| Cardiology | 1 | 2012 | 1702 | 0.050 |
Why?
|
| Child | 5 | 2016 | 80906 | 0.050 |
Why?
|
| Epidemiologic Methods | 1 | 2006 | 1326 | 0.050 |
Why?
|
| Habits | 1 | 2021 | 148 | 0.050 |
Why?
|
| Cognition Disorders | 1 | 2015 | 3977 | 0.050 |
Why?
|
| Hemoglobins | 2 | 2005 | 1531 | 0.050 |
Why?
|
| Private Sector | 1 | 2004 | 396 | 0.050 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2016 | 3781 | 0.040 |
Why?
|
| Immunity, Innate | 1 | 2013 | 3079 | 0.040 |
Why?
|
| American Medical Association | 2 | 2005 | 60 | 0.040 |
Why?
|
| Iron | 1 | 2009 | 1813 | 0.040 |
Why?
|
| Confidence Intervals | 3 | 2013 | 2923 | 0.040 |
Why?
|
| Malpractice | 1 | 2005 | 561 | 0.040 |
Why?
|
| Infant | 4 | 2014 | 36534 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2009 | 2146 | 0.040 |
Why?
|
| Saphenous Vein | 1 | 2022 | 519 | 0.040 |
Why?
|
| Heart Auscultation | 1 | 1999 | 33 | 0.040 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2006 | 1209 | 0.040 |
Why?
|
| Iatrogenic Disease | 1 | 2003 | 552 | 0.040 |
Why?
|
| Linear Models | 1 | 2009 | 5884 | 0.040 |
Why?
|
| Substance-Related Disorders | 1 | 2016 | 4423 | 0.040 |
Why?
|
| Geriatrics | 1 | 2024 | 394 | 0.040 |
Why?
|
| Thromboembolism | 1 | 2006 | 1003 | 0.040 |
Why?
|
| Cell Survival | 1 | 2009 | 5772 | 0.040 |
Why?
|
| Likelihood Functions | 2 | 2018 | 994 | 0.040 |
Why?
|
| Catheter Ablation | 1 | 2011 | 2787 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 11221 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 6843 | 0.040 |
Why?
|
| Stroke Volume | 2 | 2023 | 5624 | 0.040 |
Why?
|
| Fumarates | 1 | 2018 | 132 | 0.040 |
Why?
|
| Inpatients | 2 | 2021 | 2570 | 0.040 |
Why?
|
| Pallor | 1 | 1997 | 5 | 0.040 |
Why?
|
| Pregnancy | 2 | 2017 | 30260 | 0.040 |
Why?
|
| Probability | 1 | 2003 | 2479 | 0.040 |
Why?
|
| Value of Life | 1 | 1997 | 98 | 0.040 |
Why?
|
| Survival Rate | 1 | 2011 | 12828 | 0.040 |
Why?
|
| Hospitals | 2 | 2011 | 3886 | 0.030 |
Why?
|
| Mitral Valve Stenosis | 1 | 1999 | 342 | 0.030 |
Why?
|
| Fractures, Bone | 1 | 2009 | 2062 | 0.030 |
Why?
|
| Diastole | 1 | 1999 | 785 | 0.030 |
Why?
|
| Prepaid Health Plans | 1 | 1996 | 9 | 0.030 |
Why?
|
| Administrative Personnel | 1 | 1997 | 185 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2020 | 891 | 0.030 |
Why?
|
| Thrombolytic Therapy | 1 | 2005 | 2055 | 0.030 |
Why?
|
| Radiography | 1 | 2007 | 6983 | 0.030 |
Why?
|
| Amides | 1 | 2018 | 451 | 0.030 |
Why?
|
| Taiwan | 1 | 2017 | 521 | 0.030 |
Why?
|
| Etodolac | 1 | 2015 | 19 | 0.030 |
Why?
|
| Regression Analysis | 1 | 2005 | 6339 | 0.030 |
Why?
|
| Stents | 2 | 2018 | 3195 | 0.030 |
Why?
|
| Bronchi | 1 | 2019 | 848 | 0.030 |
Why?
|
| Respiratory System Agents | 1 | 2014 | 30 | 0.030 |
Why?
|
| Ethics, Institutional | 1 | 1994 | 38 | 0.030 |
Why?
|
| Cell Line | 1 | 2009 | 15597 | 0.030 |
Why?
|
| Standard of Care | 1 | 2019 | 568 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 13499 | 0.030 |
Why?
|
| England | 1 | 1996 | 533 | 0.030 |
Why?
|
| Echocardiography | 1 | 2007 | 5050 | 0.030 |
Why?
|
| Antipsychotic Agents | 1 | 2007 | 3081 | 0.030 |
Why?
|
| Medical Record Linkage | 1 | 2015 | 286 | 0.030 |
Why?
|
| Phentermine | 1 | 2013 | 31 | 0.030 |
Why?
|
| Salicylates | 1 | 2014 | 128 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2006 | 10098 | 0.030 |
Why?
|
| Treatment Refusal | 1 | 1997 | 433 | 0.030 |
Why?
|
| Policy | 1 | 2017 | 513 | 0.030 |
Why?
|
| Regional Health Planning | 1 | 1994 | 95 | 0.030 |
Why?
|
| Cyclobutanes | 1 | 2013 | 57 | 0.030 |
Why?
|
| Dissent and Disputes | 1 | 1994 | 150 | 0.030 |
Why?
|
| Mental Competency | 1 | 1994 | 179 | 0.030 |
Why?
|
| Appetite Depressants | 1 | 2013 | 108 | 0.030 |
Why?
|
| Group Processes | 1 | 1994 | 226 | 0.030 |
Why?
|
| Conjunctiva | 1 | 1997 | 477 | 0.030 |
Why?
|
| Data Mining | 1 | 2018 | 562 | 0.030 |
Why?
|
| Bronchoscopy | 1 | 2019 | 913 | 0.030 |
Why?
|
| Sulfones | 1 | 2015 | 448 | 0.030 |
Why?
|
| United States Federal Trade Commission | 1 | 2012 | 10 | 0.030 |
Why?
|
| Calcium | 1 | 2006 | 5794 | 0.030 |
Why?
|
| Peer Group | 1 | 2018 | 702 | 0.030 |
Why?
|
| Heart Arrest | 1 | 2003 | 1516 | 0.030 |
Why?
|
| Anastomosis, Surgical | 1 | 2016 | 992 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2015 | 592 | 0.030 |
Why?
|
| Sex | 1 | 2012 | 52 | 0.030 |
Why?
|
| Massachusetts | 2 | 2016 | 8888 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2017 | 1826 | 0.020 |
Why?
|
| Peptic Ulcer | 1 | 2013 | 214 | 0.020 |
Why?
|
| Lipids | 1 | 2023 | 3342 | 0.020 |
Why?
|
| Hyperuricemia | 1 | 2015 | 222 | 0.020 |
Why?
|
| Aging | 1 | 2011 | 8744 | 0.020 |
Why?
|
| Friends | 1 | 2012 | 149 | 0.020 |
Why?
|
| Consumer Product Safety | 1 | 2012 | 122 | 0.020 |
Why?
|
| Cerebrovascular Disorders | 1 | 2018 | 1484 | 0.020 |
Why?
|
| Obesity | 1 | 2013 | 13091 | 0.020 |
Why?
|
| Blogging | 1 | 2010 | 15 | 0.020 |
Why?
|
| British Columbia | 1 | 2011 | 240 | 0.020 |
Why?
|
| Electronic Prescribing | 1 | 2011 | 115 | 0.020 |
Why?
|
| Life Expectancy | 1 | 1997 | 1248 | 0.020 |
Why?
|
| Consensus | 1 | 2020 | 3210 | 0.020 |
Why?
|
| Obstetrics | 1 | 2017 | 681 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2011 | 187 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2014 | 1642 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2023 | 3941 | 0.020 |
Why?
|
| Truth Disclosure | 1 | 1994 | 434 | 0.020 |
Why?
|
| Education, Pharmacy | 1 | 2009 | 38 | 0.020 |
Why?
|
| Drug Information Services | 1 | 2009 | 51 | 0.020 |
Why?
|
| Medical Informatics Applications | 1 | 2010 | 180 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2014 | 26420 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2015 | 1480 | 0.020 |
Why?
|
| Directive Counseling | 1 | 2010 | 171 | 0.020 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 1323 | 0.020 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2012 | 878 | 0.020 |
Why?
|
| Urban Health Services | 1 | 2009 | 177 | 0.020 |
Why?
|
| Alendronate | 1 | 2009 | 174 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2021 | 8740 | 0.020 |
Why?
|
| Dibenzothiazepines | 1 | 2007 | 102 | 0.020 |
Why?
|
| Ibuprofen | 1 | 2009 | 229 | 0.020 |
Why?
|
| Florida | 1 | 2008 | 417 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2015 | 873 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 6786 | 0.020 |
Why?
|
| Writing | 1 | 2009 | 200 | 0.020 |
Why?
|
| Physicians, Family | 1 | 2009 | 349 | 0.020 |
Why?
|
| Spironolactone | 1 | 2010 | 415 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2017 | 2601 | 0.020 |
Why?
|
| Neoplasms | 1 | 2015 | 22365 | 0.020 |
Why?
|
| Stress, Physiological | 1 | 2013 | 1409 | 0.020 |
Why?
|
| Diuretics | 1 | 2009 | 614 | 0.020 |
Why?
|
| Professional Competence | 1 | 2009 | 430 | 0.020 |
Why?
|
| Animals | 3 | 2019 | 169222 | 0.020 |
Why?
|
| Risperidone | 1 | 2007 | 383 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2012 | 1542 | 0.020 |
Why?
|
| Financial Management, Hospital | 1 | 2005 | 70 | 0.020 |
Why?
|
| Health Services for the Aged | 1 | 2007 | 264 | 0.020 |
Why?
|
| Lobbying | 1 | 2005 | 32 | 0.010 |
Why?
|
| Defensive Medicine | 1 | 2005 | 47 | 0.010 |
Why?
|
| Mortality | 1 | 2016 | 2910 | 0.010 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2008 | 881 | 0.010 |
Why?
|
| Facility Regulation and Control | 1 | 2004 | 25 | 0.010 |
Why?
|
| Insurance, Liability | 1 | 2005 | 100 | 0.010 |
Why?
|
| Quinolones | 1 | 2007 | 389 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2017 | 2599 | 0.010 |
Why?
|
| Transcription Factors | 1 | 2024 | 12165 | 0.010 |
Why?
|
| Clozapine | 1 | 2007 | 509 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 1997 | 7140 | 0.010 |
Why?
|
| Ethics, Professional | 1 | 2004 | 100 | 0.010 |
Why?
|
| Medically Uninsured | 1 | 2008 | 840 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2019 | 9536 | 0.010 |
Why?
|
| Smoking Cessation | 1 | 2014 | 2085 | 0.010 |
Why?
|
| Opioid-Related Disorders | 1 | 2017 | 2188 | 0.010 |
Why?
|
| California | 1 | 2006 | 1438 | 0.010 |
Why?
|
| Mice | 1 | 2009 | 82024 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2013 | 10757 | 0.010 |
Why?
|
| Policy Making | 1 | 2005 | 546 | 0.010 |
Why?
|
| Emotions | 1 | 2012 | 2766 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1995 | 4261 | 0.010 |
Why?
|
| Health Promotion | 1 | 2012 | 2210 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 20757 | 0.010 |
Why?
|
| Dementia | 1 | 2007 | 2740 | 0.010 |
Why?
|
| Observer Variation | 1 | 1997 | 2618 | 0.010 |
Why?
|
| ROC Curve | 1 | 1997 | 3628 | 0.000 |
Why?
|